Research study for people with Plaque Psoriasis

Study Summary

The University of Chicago and Dr. Petronic-Rosic are conducting a study to prospectively collect and document information about the long-term safety of Enbrel® treatments used in the management of moderate to severe plaque psoriasis. It is anticipated that such information will help us better understand long-term side effects from the use of Enbrel®. Psoriasis is a chronic inflammatory disorder that affects approximately 2 percent of the world’s population. Plaque psoriasis is the most common form causing dry, red skin lesions (plaques) covered with silvery scales. The plaques itch or feel sore and may occur anywhere on your body, including your genitals and the soft tissue inside your mouth. You may have just a few plaques or many, and in severe cases, the skin around your joints may crack and bleed.

Enbrel is not an experimental drug; it is approved by the Food and Drug Administration (FDA) for the treatment of plaque psoriasis.

If you are screened and qualified to participate, you will first have a baseline visit. Then, there is a five-year follow up period consisting of clinic visits as determined by your doctor but will be no less than twice yearly, approximately every six months. If you and your doctor decide to discontinue the use of Enbrel® you are still eligible to participate in the full duration of the study. At the five-year mark you will be seen for an end of study visit. During your study visits you will receive a routine physical exam and fill out a questionnaire about your psoriasis.

Benefits

Although you will not receive any immediate health benefit from participating in this study, the information that is learned from your involvement in the study may help you and others in the future. Compensation for your time will be paid to you in $40 increments for each visit and may total up to $400 during your participation.

Participation Details

Initial selection criteria include:

• Must be at least 18 years of age
• The use of Enbrel® is clinically appropriate
• Must be available for clinic visits for the duration of the study
• Must meet study medical criteria as evaluated by Dr. Petronic-Rosic

Study Director: Dr. Vesna Petronic-Rosic
Department: Dermatology

For more information contact:
Christina M. Sprayberry
(773) 702-6559

IRB: #15067B